Your session is about to expire
← Back to Search
NMDA Receptor Antagonist
Memantine for Healthy Subjects
Phase 4
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 and 14 days post baseline
Awards & highlights
Study Summary
This study is evaluating whether a drug may help improve auditory processing for individuals with schizophrenia.
Eligible Conditions
- Healthy Subjects
- Schizophrenia
- Schizoaffective Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 and 14 days post baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 and 14 days post baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Gamma Auditory Steady-state Response (ASSR). The Primary Unit of Measure of Auditory Steady State Response (ASSR) is Gamma Evoked Power (γEP), Expressed as "Microvolts-squared".
Mismatch Negativity (MMN); Unit of Measure of MMN is Microvolts.
Prepulse Inhibition (PPI)
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: MemantineActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,121 Previous Clinical Trials
1,520,882 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger